BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Alkermes plc (ALKS) Completes Secondary Offering of 24,150,000 Ordinary Shares Held by Elan Corporation PLC (ELN)


3/13/2012 9:30:43 AM

DUBLIN--(BUSINESS WIRE)--Alkermes plc (NASDAQ: ALKS) (“Alkermes”) today announced the completion of an underwritten public offering of 24,150,000 ordinary shares held by a subsidiary of Elan Corporation, plc (“Elan”) at a price to the public of $16.50 per share, which includes 3,150,000 ordinary shares in connection with the full exercise by the underwriters of their option to purchase additional shares. Alkermes did not receive any proceeds from the offering, and its total number of ordinary shares outstanding did not change as a result of the offering. Citigroup, Jefferies & Company, Inc. and Morgan Stanley acted as joint book-running managers. Berenberg Bank and Cowen and Company, LLC acted as co-managers for the offering. The Elan subsidiary continues to own 7,750,000 ordinary shares, which are subject to transfer restrictions set forth in a shareholder’s agreement by and between Alkermes, Elan and the Elan subsidiary.

Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->